Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Tuberculosis
Interventions: Epistem Genedrive® and MolBio Truenat™; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Child Disruptive Behavior Disorders, Parent Child Relationship, Parent Management Training, Peer Support, Child Behavior Problems, Challenging Behavior, Positive Parenting
Interventions: FAST-B PEERS, FAST-B (First Approach Skills Training - Behavior); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoporosis
Interventions: risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet); Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 4
States / cities: Davis, California • Duarte, California • South Pasadena, California + 1 more

Conditions: Hepatitis C, Drug Use
Interventions: Rapid Treatment strategy, Usual Care (facilitated referral); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Food Selection
Interventions: Calorie Labels, Exercise Labels, No Labels; Behavioral
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Validation of Oximeter System
Interventions: Mespere Venous Oximeter, Avoximeter 4000; Device
Lead sponsor: Mespere Lifesciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Suicidal Ideation
Interventions: Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning; Drug · Other · Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Fort Hood, Texas • San Antonio, Texas

Conditions: Coronary Artery Disease
Interventions: Vessel Fractional Flow Reserve; Diagnostic Test
Lead sponsor: Erasmus Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Covid-19 Antibody Test, Short Clip videos; Diagnostic Test · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Hepatitis C, Chronic
Interventions: HCV RNA screening; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Infectious Gastroenteritis
Interventions: FilmArray™ Gastrointestinal (GI) Panel; Device
Lead sponsor: BioFire Diagnostics, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 1,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Kansas City, Missouri • Columbus, Ohio + 2 more

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: 14C-VX-407; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cardiac Surgery
Interventions: LiDCO rapid monitor; Device
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sleep Disturbance, Sleep Quality
Interventions: 2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo; Dietary Supplement
Lead sponsor: Cannabis Science Innovations, LLC; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Diffuse Large B-cell Lymphoma
Interventions: RAD001, LBH589, Doublet (RAD001 and LBH589); Drug
Lead sponsor: Anne Beaven, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mobility Disability, Walking Difficulty
Interventions: Brief Daily At-Home Strength Training Program, Loss Aversion Messaging, Standard Adherence Reminder Messaging; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Shock, Septic
Interventions: Lactated Ringer, Normal Saline, Plasma-lyte; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 17 Years
Enrollment: 9,041 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Influenza
Interventions: Oseltamivir, Peramivir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Baltimore, Maryland

Conditions: Trauma, Rapid Sequence Intubation
Interventions: Ketamine, Etomidate, Propofol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

Examining the Feasibility, Acceptability, and Fidelity of Utilizing Parent Training Graduates as Peer Supports

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

HCV Seek, Test and Rapid Treatment for Young PWID

The Effect of Menu Labels on Calories Ordered in Hispanics

Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department

Fast Assessment of STenosis Severity- FASTII Study

RADx-UP CDCC Rapid Research Pilot Program "Culturally-relevant Community Connections (C3) to Increase COVID-19 Testing

Rapid HCV RNA Testing and LInkage to Care

Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

LiDCO Monitor Study

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Rapid HIV Tests for Women Late in Pregnancy and During Labor

Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Prospective Study of Induction Medications Used in the Trauma RSI

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2